Fertility Sparing Therapy for Patients With Stage IA G2 Endometrial Cancer

NCT06468215 · tracked via the Priya Life Science China tracker

Sponsor

Peking University People's Hospital

Phase

Not applicable

Started

2024-06-21

Last updated

2026-08-21

Condition(s) studied

Carcinoma, EndometrioidFertility Preservation

Investigational drug(s) / intervention(s)

Treatment Option 1 is a single-drug regimen, with oral medroxyprogesterone acetate (MPA) 500mg/d or MA 320mg/d.

Treatment Option 1 is a single-drug regimen, with oral medroxyprogesterone acetate (MPA) 500mg/d or MA 320mg/d.: Compare the efficacy of mono-therapy with progesterone versus combined therapy to determine the best treatment option.

Study summary

Endometrial cancer (EC) is a prevalent gynecological cancer with an escalating global incidence and a decreasing age of onset. In the era of precision medicine, there is an increasing emphasis on tailoring treatments to different populations to optimize the positive impact of clinical interventions. Fertility-sparing therapies (FST) are gaining popularity for early-stage, low-grade endometrial cancer due to mounting evidence supporting favorable oncologic and pregnancy outcomes. However, consensus regarding the feasibility of fertility-sparing therapy for similar low-risk grade-2 (G2) endometrioid adenocarcinoma remains elusive. Given the uncertainties surrounding fertility-preserving therapy in patients with moderately differentiated endometrial cancer, this study aims to investigate the optimal regimen of fertility-preserving therapy for patients with IAG2.

Eligibility

Sex

FEMALE

Min age

—

Max age

45 Years

Healthy volunteers

Inclusion Criteria: * Endometrioid adenocarcinoma G2, diagnosis by pathological. * The lesion is limited to the endometrium. * FIGO (2009) staging is IA. * Age less than 45. * Strongly request to preserve fertility. * Sign informed consent. Exclusion Criteria: * The tumor has invaded the muscle layer. * FIGO (2009) stage IB or higher. * Endometrioid adenocarcinoma G1, G3, or non-endometrioid cancer * There are malignant tumors in other systems. * Have contraindications for conservative treatment or drug use. * Have been judged by the researcher to be unsuitable for childbearing.

Primary outcome measure(s)

The Time Required for Complete Remission for the First Time — 5 years
The time from the diagnosis of G2 endometrioid carcinoma to the first complete remission after fertility-preserving treatment.（year）

Trial sites (1)

Facility	City	Region	Status
Peking University People's Hospital	Beijing	Beijing Municipality	Recruiting

More Peking University People's Hospital trials in China

Cadherin 3(CDH3)-Targeted PET in Lung Malignant Tumors Recruiting

Research on the Application of Patient Navigation-based Management Model of Patients After LEEP Starting soon

IFN-α in Relapse Prevention. Starting soon

ctDNA-Guided De-Escalation of Adjuvant Chemotherapy With Dalpiciclib in HR-Positive/HER2-Negative Breast Cancer Recruiting

CDK4/6 Inhibitors Combined With Endocrine Therapy for Neoadjuvant Treatment Recruiting

Other trials for the same condition

Neoadjuvant Chemotherapy Plus Camrelizumab for FIGO Stage IB1 Cervical Cancer Recruiting

Fertility-sparing Therapy for Patients With Stage IA Endometrial Cancer Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06468215 on ClinicalTrials.gov ↗ ← All trials in China